Jula Inrig Sells 311 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 311 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $13,668.45. Following the transaction, the insider directly owned 113,238 shares in the company, valued at $4,976,810.10. This represents a 0.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The stock was sold at an average price of $46.65, for a total value of $101,417.10.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $45.00, for a total value of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The stock was sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The stock was sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Price Performance

TVTX stock traded down $0.10 on Wednesday, reaching $44.70. 2,390,035 shares of the company’s stock were exchanged, compared to its average volume of 2,890,153. The stock has a fifty day moving average of $32.59 and a 200-day moving average of $32.83. Travere Therapeutics, Inc. has a twelve month low of $13.88 and a twelve month high of $48.61. The firm has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. Travere Therapeutics’s quarterly revenue was up 55.6% on a year-over-year basis. As a group, equities analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Analysts Set New Price Targets

TVTX has been the topic of a number of research analyst reports. TD Cowen boosted their target price on Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday. Wells Fargo & Company boosted their target price on Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday. HC Wainwright boosted their target price on Travere Therapeutics from $47.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday. Wedbush boosted their target price on Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wall Street Zen downgraded Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $47.83.

Institutional Investors Weigh In On Travere Therapeutics

A number of large investors have recently modified their holdings of TVTX. State of Wyoming purchased a new position in Travere Therapeutics in the fourth quarter valued at about $37,000. Torren Management LLC bought a new stake in Travere Therapeutics during the 4th quarter valued at $38,000. Comerica Bank raised its stake in Travere Therapeutics by 77.5% during the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares in the last quarter. Fifth Third Bancorp bought a new stake in Travere Therapeutics during the 1st quarter valued at $35,000. Finally, Smartleaf Asset Management LLC raised its stake in Travere Therapeutics by 69.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after acquiring an additional 487 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.